Results 101 to 110 of about 7,425 (188)

Dose-related depressive symptoms and suicidal ideation during cabergoline therapy in an adolescent with macroprolactinoma. [PDF]

JCEM Case Rep
Malik S, Al Harrasi A, Al Kiyumi MI, Al Kiyumi MH.   +3 more
europepmc   +1 more source

Use of Cabergoline in Prolactinomas

, 1998
Bromocriptine (BRC), the standard medication for prolactinomas, is effective in most cases but has a short half-life and occasional side effects. Cabergoline (CAB, Dostinex) is a potent D2-selective dopamine agonist, FDA-approved since12/1996 for ...
Victoria Pelak, MD; G. T. Liu, MD; S. L. Galetta, MD; N. Butler; A. Stein; L. Bolinger
core  

Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice. [PDF]

Pituitary
De Sousa SMC, Marcus HJ, Ovenden CD, Prevedello D, Petersenn S.   +4 more
europepmc   +1 more source

Autophagy in Pituitary Neuroendocrine Tumors (PitNETs): Molecular Mechanisms, Secretory Homeostasis, Therapeutic Resistance, and Translational Perspectives. [PDF]

Int J Mol Sci
Rizzuto I, Pepe L, Broggi G, Caltabiano R, Fiorentino V, Ieni A.   +5 more
europepmc   +1 more source

Case Report: Neurosurgery, octreotide, cabergoline, radiotherapy, pasireotide and pegvisomant - a multimodal strategy for adolescent acrogigantism. [PDF]

Front Endocrinol (Lausanne)
Dzialach L, Bogusz-Wójcik A, Moszczyńska E, Wojciechowska-Luzniak A, Zieliński G, Maksymowicz M, Witek P.   +6 more
europepmc   +1 more source

Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study. [PDF]

Pituitary
Daniel KB, Glezer A, de Queiroz NL, Correa-Silva SR, Trentin MBF, Fujiwara MT, Benetti-Pinto CL, Kasuki L, Tavares LAG, do Rosário PWS, Garmes HM.   +10 more
europepmc   +1 more source

A Rare Behavior of Microprolactinoma with Significant Fluctuation in Size During Pregnancy. [PDF]

Am J Med Open
Ghafarzadeh-Rad S, Valizadeh S, Ashayeri H.   +2 more
europepmc   +1 more source

Correction: Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. [PDF]

Pituitary
Mamelak AN, Fox R, Rosenberg Y, Gomez D, Cui Y, Shlomo AB, Labadzhyan A, Liu NA, Bonert V, Cooper O.   +9 more
europepmc   +1 more source

The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation. [PDF]

Cureus
Haouani H, Elbakkali H, Belharty N, Oukerraj L, Cherti M.   +4 more
europepmc   +1 more source

Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials. [PDF]

JAMA Psychiatry
Amin-Esmaeili M, Farokhnia M, Mojtabai R, Leggio L, Johnson RM, Susukida R.   +5 more
europepmc   +1 more source